Absci's Lead Drug ABS-201 Shows Positive Phase 1 Safety, PK Data; Advances to Next Stage
ABSI has more than doubled off its 52-week low of $2.24.
Summary
Absci reported positive interim Phase 1 data for its lead drug candidate, ABS-201, an anti-prolactin receptor antibody. The trial demonstrated favorable safety and pharmacokinetics, with no serious adverse events and a long estimated half-life of at least 65 days, supporting a potential infrequent dosing schedule. This de-risking data allows the drug to advance into multiple ascending dose studies. This news provides concrete positive clinical progress following the company's Q1 report which highlighted revenue declines. Interim proof-of-concept data is expected in the second half of 2026, with a Phase 2 trial for endometriosis planned for later this year.
At the time of this announcement, ABSI was trading at $7.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $2.24 to $8.57. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.